NetworkNewsWire
Editorial Coverage: Gene therapy is hot on the trail of killing
cancer, and companies that deliver cures could see blockbuster
returns.
Pioneering a new paradigm in cancer therapeutics,
Genprex Inc. (NASDAQ: GNPX) (GNPX
Profile) is leveraging its patented technology
platform to deliver powerful tumor-suppressing genes directly into
cancer cells. Calithera Biosciences Inc. (NASDAQ:
CALA) is looking for cures for cancer and other
life-threatening diseases by discovering, developing and
commercializing novel, small-molecule drugs that target tumor and
immune cell metabolism. Adaptimmune Therapeutics plc
(NASDAQ: ADAP) is developing novel cancer immunotherapy
products for cancer patients by engineering T-cells to target and
destroy cancer. Agenus Inc. (NASDAQ: AGEN) is
working on the discovery and development of therapies that engage
the body's immune system to fight cancer by pursuing combination
approaches that leverage a broad range of antibody therapeutics,
proprietary cancer vaccine platforms and adoptive cell therapies.
G1 Therapeutics Inc. (NASDAQ: GTHX) is advancing
three clinical-stage programs designed to enable more effective
combination treatment strategies and improve patient outcomes
across multiple oncology indications.
- Cancer remains one of the most frustratingly difficult diseases
to cure.
- New gene-based therapeutic paradigms are now in play.
- With breakthrough technologies, gene therapy is on the cusp of
curing the incurable.
- Biotech companies that deliver these cures could also deliver
blockbuster returns.
To view an infographic of this editorial, click here.
Blockbuster Potential
Even though gene therapy is closing in on cancer, it remains as
yet an unpredictable industry. However, biotech companies are in a
feverish hunt for breakthroughs, and gene therapy could hold the
keys. Tremendous advances have been made in gene-based
therapeutics, and companies, such as Genprex
Inc. (NASDAQ: GNPX), with the potential to make
breakthroughs could deliver blockbuster returns.
Genprex is collaborating with MD Anderson Cancer Center to
further develop and test its patented multimodal technology,
currently in a Phase II clinical trial. The company recently caught
the attention of a research-driven investment bank, Noble
Financial, which initiated coverage of Genprex with an Outperform rating and a price target that’s about
triple current levels.
Unlike other gene therapy approaches, Genprex’s method doesn’t
inject a patient with a genetically modified virus and doesn’t edit
or modify a patient's genes. Instead, the company’s revolutionary
technology encapsulates a powerful proven cancer-suppressor gene
(TUSC2) in cholesterol nanoparticles (nanovesicles) engineered to
target cancer cells. Since the body is familiar with breaking down
cholesterol, Genprex's lead product, Oncoprex(TM), delivers its TUSC2 gene directly to the
targeted cells, readily passing through the small blood vessels
that form around tumors. Like a magnet, the encapsulated cancer
suppressor genes are first attracted to the opposite electrical
charge of tumors then enter malignant cells to begin their
work.
The loss of tumor-suppressor genes is the most common genetic
mutation in cancer cells. When delivered to a cancer cell, the
TUSC2 gene has been shown to restore the genetic coding required to
produce more tumor suppressors. TUSC2 has been shown to be well
tolerated by healthy cells, and importantly, the payload is taken
up by tumor cells at up to 25 times the rate they’re taken up by
normal cells. Genprex hopes its gene therapy technology will
restore normal expression levels of tumor suppressor genes,
inducing cell death (apoptosis), inhibiting tumor progression and
subsequently prolonging survival of cancer patients.
Due to its unprecedented dual mechanism of action (gene therapy
and immunotherapy), Genprex’s Oncoprex is identified as an
immunogene therapy. Oncoprex is designed to restore the genetic
coding of tumor suppressor genes in cells (gene therapy) plus
stimulate the body’s natural anti-cancer immune response
(immunotherapy).
Cutting-Edge Platform
Most currently approved cancer regimens target only single
molecules, or a single specific genetic abnormality. Oncoprex’s
multimodal mechanism of action interrupts cell signaling pathways
that cause replication and proliferation of cancer cells,
re-establishes the pathways for cell death in cancer cells and
modulates the immune response against cancer cells. Genprex
clinical data indicate that Oncoprex, in combination with targeted
therapies and immunotherapies, is significantly more effective than
single drugs alone. Oncoprex has also demonstrated fewer side
effects and less toxicity than many other lung cancer drugs.
Currently approved targeted therapies for advanced non-small
cell lung cancer are only effective in a minority of patients, and
eventually most patients become resistant to the treatments.
Roughly 80% of lung cancers are non-small cell lung cancer, and the
dismal 1% five-year survival rates haven’t improved in over a
quarter century.
Genprex is well into Phase II clinical trials with Oncoprex for
the treatment of the deadliest type of tumor, non-small cell lung
cancer (NSCLC). Preliminary
results from the ongoing trial to date are encouraging. Using
Oncoprex in combination with Roche's erlotinib showed disease
control rates of 78%, which substantially exceed the 58% disease
control rates demonstrated in other drug combination trials.
In addition, more than 40% of patients had tumor regression, and
one patient — out of nine evaluated to date in Genprex’s Phase II
drug combination trial — experienced what’s called a complete
response. The patient, suffering with metastatic NSCLC, had
complete disappearance of both the lung primary tumor as well as
the metastasized cancer in the lung, liver and lymph nodes.
Genprex's cutting-edge platform for the targeted delivery of
gene therapeutics also has wide-ranging potential applications for
the treatment of various other types of cancer, such as head and
neck, renal cell (kidney), glioblastoma and soft-tissue cancer,
among others.
Genprex holds more than 30 patents and 2 patents pending for its
platform technologies and targeted molecular therapies. The
company’s promising pipeline includes Oncoprex in combination with
another cancer drug, Tarceva, in a Phase II clinical trial; and
Oncoprex Immunogene therapy in preclinical development.
The company is conducting ongoing research to find biomarkers to
identify patients most likely to benefit from Genprex treatments,
as well as other drugs that will be synergistic with Genprex gene
therapies. Given the enormous potential and vast unmet medical
need, Genprex plans to apply for Fast Track, Breakthrough or RMAT
designation from the FDA.
What’s Next?
Preliminary results show that Oncoprex has the potential to
become an effective add-on therapy for the treatment of deadly
non-small cell lung cancer. Genprex plans to expand the current
erlotinib-Oncoprex trial to multiple research centers and conduct
more new trials.
If Phase II results are as positive as preliminary indications,
it could spark a rally in the shares and possibly even lure a large
biotechnology or pharma company to sign a high-value partnership
with Genprex. Should such a strategic partnership to commercialize
Genprex’s technology transpire, it could potentially generate
enormous value for the company's shareholders.
Without any of this in the bank, Noble Financial has already
pegged the stock to reach $5 a share, nearly
triple from today’s closing price. With such positive preliminary
results and blockbuster potential, it is possible that Noble’s
target price might even be low. Genprex is certainly one to
watch.
Seeking Biotech Cancer Cures
Other companies are also clamoring for attention in the
potential cancer-cure space.
Calithera Biosciences Inc. (NASDAQ: CALA) is a
clinical-stage biopharmaceutical company focused on fighting cancer
and other life-threatening diseases by discovering, developing and
commercializing novel small-molecule drugs that target tumor and
immune cell metabolism. The company believes certain small-molecule
drugs can slow tumor growth through controlling key metabolic
pathways in the tumor and immune cells. Tumor metabolism and tumor
immunology are promising new interrelated fields for cancer drug
discovery. Recent clinical successes have demonstrated the
potential to slow abnormal cell growth and create fundamentally new
therapies for cancer patients.
Adaptimmune Therapeutics plc (NASDAQ: ADAP) is
a clinical-stage biopharmaceutical company researching the
development of novel cancer immunotherapy products for cancer
patients. The company’s unique Specific Peptide Enhanced Affinity
Receptor (SPEAR) T‑cell platform enables the engineering of T-cells
to target and destroy cancer across multiple solid tumors.
Adaptimmune’s affinity-enhanced T-cell therapies work with the
immune system to improve detection and targeting of cancer cells,
resulting in destruction of those cancer cells. The company has
clinical trials ongoing for three wholly owned SPEAR T-cells in
multiple solid-tumor indications.
Agenus Inc. (NASDAQ: AGEN) is a clinical-stage
immuno-oncology company examining the discovery and development of
therapies that engage the body's immune system to fight cancer. The
company vision is to expand the patient populations benefiting from
cancer immunotherapy by pursuing combination approaches that
leverage a broad range of antibody therapeutics, proprietary cancer
vaccine platforms and adoptive cell therapies. Agenus believes that
combination therapies and a deep understanding of each patient’s
cancer will be key drivers of success in substantially expanding
the benefits from current immuno-oncology therapies.
G1 Therapeutics Inc. (NASDAQ: GTHX) is a
clinical-stage biopharmaceutical company working on the discovery,
development and delivery of innovative therapies that improve the
lives of those affected by cancer. The company is advancing three
clinical-stage programs. Trilaciclib and lerociclib are designed to
enable more effective combination-treatment strategies and improve
patient outcomes across multiple oncology indications. G1T48 is a
potential best-in-class oral selective estrogen receptor degrader
(SERD) for the treatment of ER+ breast cancer. G1 also has an
active discovery program focused on cyclin-dependent kinase
targets.
With cancer killing more than 600,000 people in
2018, companies involved in the work of curing this dreaded
disease are certain to capture the attention of those looking to
invest in technology with the potential to save.
For more information on Genprex, visit Genprex Inc.
(NASDAQ: GNPX)
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content
distribution company that provides (1) access to a network of wire
services via NetworkWire to
reach all target markets, industries and demographics in the most
effective manner possible, (2) article and editorial syndication to
5,000+ news outlets (3), enhanced press release services to ensure
maximum impact, (4) social media distribution via the Investor
Brand Network (IBN) to nearly 2 million followers, (5) a full array
of corporate communications solutions, and (6) a total news
coverage solution with NNW Prime. As a
multifaceted organization with an extensive team of contributing
journalists and writers, NNW is uniquely positioned to best serve
private and public companies that desire to reach a wide audience
of investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024
